secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-021958
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics appoints Alex Sapir CEO, reports Q1 net loss of $24.8M, FTX-6058 on clinical hold
--------------------------------------------------------------------------------

- Alex Sapir appointed CEO/President effective July 1, 2023; he will serve as special advisor until then.
- Esther Rajavelu resigned as CFO effective Apr 21, 2023; Robert Gould appointed interim principal financial officer.
- FDA placed FTX-6058 for sickle cell disease on full clinical hold in Feb 2023; active discussions ongoing.
- Phase 3 REACH trial of losmapimod in FSHD enrollment on track to complete in second half of 2023.
- Q1 2023 net loss $24.8M; cash, equivalents, and marketable securities $297.8M; cash runway into mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/fulc-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer